key: cord-0687146-u19fnx7e
authors: Sarcinelli, Michelle Alvares; Martins da Silva, Thalita; Artico Silva, Andressa Daniele; Ferreira de Carvalho Patricio, Beatriz; Mendes Paiva, Flávia Costa; Santos de Lima, Raissa; Leal da Silva, Manuela; Antunes Rocha, Helvécio Vinícius
title: The pulmonary route as a way to drug repositioning in COVID-19 therapy
date: 2021-02-24
journal: J Drug Deliv Sci Technol
DOI: 10.1016/j.jddst.2021.102430
sha: 94e0f96d0cd37ab98fa0735e972c2ad6bdb18ea4
doc_id: 687146
cord_uid: u19fnx7e

INTRODUCTION: The outbreak of the disease caused by the new coronavirus (COVID-19) has been affecting society’s routine and its patterns of interaction worldwide, in addition to the impact on the global economy. To date, there is still no clinically effective treatment for this comorbidity, and drug repositioning might be a good strategy considering the established clinical safety profile. In this context, since COVID-19 affects the respiratory tract, a promising approach would be the pulmonary drug delivery. OBJECTIVE: Identify repurposing drug candidates for the treatment of COVID-19 based on the data of ongoing clinical trials and in silico studies and also assess their potential to be applied in formulations for pulmonary administration. METHOD: A narrative literature review was conducted between June and July 2020, by extracting the results from Clinical Trials, PubMed, Web of Science and Science Direct databases. RESULTS: By crossing the results obtained from diverse sources, 21 common drugs were found, from which only 4 drugs presented studies of pulmonary release formulations, demonstrating the need for greater investment and incentive in this field. CONCLUSION: Even though the lung is a target that facilitates viral infection and replication, formulations for pulmonary delivery of suitable drugs are still lacking for COVID-19 treatment. However, it is indisputable that the pandemic constitutes a concrete demand, with a profound impact on public health, and that, with the appropriate investments, it will give the pharmaceutical industry an opportunity to reinforce the pulmonary delivery field.

has shown very positive results in the treatment of other lung diseases, which may be related to its rapid 23 onset, low metabolic activity at the site, lower risk of adverse effects, among others [10] [11] [12] . 24

Thus, this article aims to present possible drugs that are candidates for repositioning via a 25 pulmonary formulation for the treatment of COVID-19, the scientific basis for its use, as well as the 26 related technological and regulatory aspects. It is expected to stimulate the debate and, mainly, to present 27 a preliminary evaluation model for the selection of drugs with a view to repositioning in a pandemic 28 situation and the need for emergency actions to attendant public health demands. 29 30

Methods 31

The present study constitutes a literature integrative review [13] , which aimed to identify 32 repositioning drugs candidates for pulmonary administration for the COVID-19 treatment. 33

Clinical trials drug selection residues [35, 36] . 123

The article by Chandra and coworkers [27] , 2020 target the EndoU protein and reported 124 interactions with all the amino acid residues that are part of the active protein site (His235, Thr341, 125

Tyr343, His250, Ser294 and Lys290) [37, 38] . 126

In addition to the mentioned criteria, the 3D structures used for in silico tests were evaluated, as a 127 non-excluding criterion, comparing them with the 3D conformation that performs the biological function. 128

The Mpro enzyme has biological activity in its dimeric form [32] , however only the work published by 129

Elmezayen and corworkers [8] performed the in silico simulations using the native form of Mpro. The 130 other evaluated articles just cited the use of the enzyme in its monomeric form. Likewise, the enzyme 131

EndoU performs biological function in its hexameric form [38] , however Chandra and coworkers [27] 132 used its dimeric form (PDBid: 6W01) to perform the simulations. Tariq and coworkers [15] uses RBD as 133 a molecular target in monomeric form, its biologically active form [39] (PDBid: 6Y84). 134 135

Drug repositioning approaches using in silico tools, such as molecular docking studies, virtual 137 screening, and dynamic simulation accelerate the identification of promising drugs to treat specific 138 pathologies [12, 13] . However, analyzing the results obtained in this work is possible to realize that this 139 strategy does not seem to be sufficiently explored by the pharmaceutical industry. Among 291 drugs 140 currently evaluated in clinical trials, only 12 were also indicated by in silico studies: argatroban, 141 artemisinin, atovaquone, bicalutamide, chloroquine, deferoxamine, doxycycline, estradiol, mefloquine, 142 montelukast, oseltamivir and remdesivir ( Figure 2 ). This demonstrates that applying the results from 143 academy to the clinical practice is still a challenging process. 144

It was also observed that different strategies were used to select drugs in the two cases evaluated 145 herein. While in silico trials consider the particularities of the virus and possible drug-receptor 146 J o u r n a l P r e -p r o o f 7 interactions to deduce which drugs would be suitable for the treatment of COVID-19, the drugs on 147 clinical trials focus on symptomatic treatment of the disease. Thus, in silico studies mainly indicate 148 antivirals, capable of inhibiting virus replication, while clinical trials explore the most diverse 149 pharmacological among classes, such as antibiotics and anticoagulants, others. 150 A combination of the aforementioned strategies is probably more recommended, since antivirals 151 could be particularly viable in moderate cases, preventing the worsening of the disease and reducing 152 overcrowding in health care systems [40, 41] . However, for patients in severe conditions, it is necessary 153 another strategy treatment due to the associated immune dysregulation [42] . 154

After searching for the names of each drug previously mentioned combined with keywords that 155 relate them with pulmonary drug release, no results were considered relevant for the following drugs: 156 argatroban, artemisinin, atovaquone, bicalutamide, chloroquine, deferoxamine, mefloquine, and 157 remdesivir. For doxycycline (DOX), estradiol, montelukast (MLK), and oseltamivir the search returns the 158 results described in Figure 3 , identifying 278 research articles. After applying the eligibility and exclusion 159 criteria, 19 papers were included in this review. 160

The four selected drugs belong to two main pharmacology groups: drugs with a systemic target, 161

with an antibiotic or anti-inflammatory action, and drugs with a specific viral molecular target. The drugs 162

in the first groups are: doxycycline (DOX), estradiol and montelukast (MLK). The only drug in the 163 second group is oseltamivir. 164 DOX is a broad-spectrum antibacterial drug commonly associated with an anti-inflammatory 165 effect. Its ability to reduce the inflammatory processes associated with cystic fibrosis and chronic lung 166 diseases has been documented [43, 44] . Regarding COVID-19, its ability to interact with the viral SARS-167

CoV-2 was evaluated in silico through molecular docking studies, showing that this drug could interact 168 with specific sites of both main viral replication protease (Mpro) and S1 protein (Table 1) [15] . 169

For some decades, estradiol (17β-estradiol), has been evaluated as a safer alternative to the use of 170 artificial hormones [45] . Concerning COVID-19, Pant and corworkers [15] , through computational 171 methods, proposed that estradiol has a potential for interaction and inhibition of the main protease of 172 SARS-CoV-2 (Table 1) . 173 MLK, a cysteinyl-leukotriene type 1 (CysLT1) receptor antagonist, inhibits the inflammation 174 process, especially the ones caused by leukotriene D4 [46, 47] . It is used, not only in asthma treatment, but 175 also to prevent wheezing, chest tightness, cough, and exercise-induced bronchospasm in adults and 176 children [47, 48] . Besides that, it could be used to treat other neutrophil activation diseases, such as 177 seasonal allergies [49] . Virtual screening and molecular dynamics studies identified that MLK could 178 function as a protease inhibitor of SARS-CoV-2 (Table X) [14] . 179

Oseltamivir phosphate is a prodrug that is converted into its carboxylate derivative, recommended 180 by the World Health Organization as the first-line treatment against influenza virus. It is available for oral 181 administration and was first registered as Tamiflu ® by Hoffmann-La Roche Ltd [50] . Al-Khafaji and 182 J o u r n a l P r e -p r o o f 8 coworkers evaluate the covalent docking of several antiviral drugs and oseltamivir showed a good ability 183 to interact with SARS-CoV-2 Mpro (Table 1 ) [17] . 184 185

COVID-19 is a disease that affects the respiratory tract. Evidence suggests that the angiotensin-187 converting enzyme receptor 2 (ACE2) may facilitate SARS-CoV-2 entry cells [51] , and as a healthy lung 188 tissue has alveolar epithelial cells expressing ACE2 [52] , it is highlighted that the lungs can be considered 189 a primary target to promote viral invasion and replication. Therefore, the use of pulmonary drug delivery 190 could be considered a promising alternative to fight against this disease and considering the main findings 191 of academia that were discussed herein, the technology developed could be rapidly transferred as to 192 enable the clinical treatment of COVID- 19. 193 It is quite evident that the pulmonary route is an extremely important target for distinguishing 194 diseases, likewise asthma and DPOC. Clearly, not only COVID-19 motivates investments in this segment, 195 but also could be an acceleration force for new research and even a redirection of several companies' 196 portfolio. At this moment, pharmaceutical laboratories are facing a concrete demand, with a profound 197 impact on public health. Investment in research and development of formulations for pulmonary release 198 could bring to these institutions a character of innovation that has not been verified for a long time. 199

Drug delivery systems prove to be a highly favorable path in incremental innovation [53] , 200 essential for the development and registration of numerous drugs currently available clinically. Faced 201 with an international scenario in which the pharmaceutical sector has been envisaging serious difficulties 202 to launch innovative drugs, delivery systems can be an excellent opportunity both to attribute new 203 pharmacokinetic profiles to existing drugs and to lead them to new uses. 204

A successfully application of drug repurposing as pulmonary route is the asthma disease 205 treatment. The review published by Anderson brings several examples of drugs that were administered by 206 oral or intravenous route and became available as inhaled in order to reduce side-effects, dose, and allow 207 a prophylactic treatment [54] . A classic example was budesonide, where the oral and aerosol formulations 208 were compared and only the inhaled form showed antiasthmatic effect, proving that its local action in the 209 airways was better than systemic activity after absorption [55] . The repurpose of iloprost (Ilomedin ® ) was 210 also interesting. This drug is a prostacyclin analogue used for severe forms of peripheral arterial disease 211 that was repurposed for aerosol therapy of pulmonary hypertension (PAH). Nowadays, iloprost is 212 recommended as class I monotherapy in patients with PAH [56] . In addition, the agencies contribution 213 with documents such as the Food and Drugs and Cosmetic Act 505(b)(2) facilitates the regulatory 214 approval of drugs with changes in dosage form, strength, formulation, dosing regimen, or route of 215 administration [57] . Thus, reducing costs and time to new formulations market launching. As numerous 216 cases, COVID-19 can be a lever in the innovation process in this area, as can be concluded by everything 217 previously exposed in the article. 218 J o u r n a l P r e -p r o o f 9 In this context, considering the potential benefits of pulmonary route for COVID-19, a literature 219 search was conducted to find possible pulmonary release formulations with the drugs previously selected. 220

The relevant information of the 17 analyzed papers of pulmonary delivery of these drugs are summarized 221

in Table 2 . For DOX, dry powder inhaler (DPI) formulations are the most reported in the literature, being 222 the spray drying (SD) the most applied technique to produce this powder. It was used for producing 223 microparticles [58, 59] and also, as a drying process combined with other methodologies [60, 61] , to 224 provide the powder for the DPI. In addition to solid formulations, DOX nebulizer solutions have also 225 been reported [62] (Table 1) . 226 SD was the most used technique also for estradiol formulations and the most used excipients to 227 formulate this drug were albumin, lactose, and dipalmitoylphosphatidylcholine (DPPC) [63] (Table 1) . 228

This last one is the major phospholipid present in pulmonary surfactant, which is essential for mammalian 229 breath because its ability of solubilize poorly water-soluble molecules and reduce the surface tension in a 230 water solution [64, 65] . Due to this, the role of lung surfactant to optimize pulmonary drug delivery and 231 distribute poorly water-soluble drugs over the respiratory air-liquid interface has been reported for other 232 drugs and has been applied in pulmonary formulation of estradiol [64] . 233

Due to the lower expression of cytochrome P450 3A4 enzyme in the lungs [66] , when MLK is 234 administered via pulmonary route its metabolization is reduced compared to the liver [67] . So, the 235 pulmonary route can improves its bioavailability [68] in comparison with the oral route, for which is 236 approximately 64%, due to the first pass effect [46, 69, 70] . As MLK is used for asthma treatment, there 237 are plenty of investigations for its pulmonary administration. Probably, because of that, 6 of 8 studies 238

with MLK presented in vivo experimental data ( Table 2 ). The majority uses DPI, as microparticles, but it 239 was also possible to find one study with pressurized metered-dose inhaler (pMDI) ( Table 2 ) [68] . The SD 240 technique was widely used and several strategies were applied to increase drug release and reach the deep 241 lung, such as porous particles [67, 71] . Distinguish works evaluate the mucoadhesiveness characteristic of 242 the obtained particles, since this property could increase the formulation retention time in the pulmonary 243 region [44] . It is relevant to point it out that some of the strategy applied for this drug could be applied for 244 other ones accelerating the investigative process. 245

On the other hand, only two oseltamivir pulmonary formulations are proposed in the literature, 246

and they are presented as DPI or nebulizer solution. Both present an increase in AUC when compared to 247 other administration routes (Table 2) . Tables 2 and 3 , it is possible to observe some peculiarities of the studies with the selected 251 drugs. The first one concerns the type of device most commonly used, in up to 78.9% of the studies, 252 which is DPI. Its preponderance is superlative compared to 10.5% of solutions/suspensions for 253 nebulization. This is an excellent indication of how a given technology is more promising in terms of 254 therapeutic application. This data, in a way, agrees with the literature that, in fact, places DPI as one of 255 the most viable approaches for pulmonary drug administration [83] . The technology for obtaining the 256 release systems, in turn, accounts for 57.9% of cases using the spray drying technique. This approach is 257 already foreseen, since it is a type of processing that is commonly used for obtaining spherical shaped 258 particles, which are very useful for pulmonary administration [84] . In addition, it presents a high 259 scalability, and it is already a traditional process in the pharmaceutical industry [85] . 260

On the other hand, a parameter that is imperative for the proper understanding of the systems is No. 33, on April 17, 2019), which is the Brazilian Health Regulatory Agency, recommend evaluating 267 aerodynamic particle size distribution by cascade impactor test for formulations intended for pulmonary 268 release [86] [87] [88] . In addition, in many of the articles in which this trial was conducted, the method was not 269 adequately described or properly justified. Anyway, when the particle size results are mentioned, they are 270 below 12 µm, except for one article, which showed 26.3 µm in size [60] . These values are in accordance 271 with the general literature on pulmonary delivery systems [89, 90] . 272

Regarding the excipients use in pulmonary formulations, EMA guide emphasizes the importance 273 of using excipients with well-established use for pulmonary release and, if this is not possible, safety 274 studies for such application must be carried out [86] . The FDA provides a list of the excipients used in the 275 approved for various administration routes, which can facilitate the development or repositioning of drugs 276 via the pulmonary route [91] . Among them, lactose [73, 78, 79] , mannitol [46, 76] , and lecithin [50, 75] (Table 2) and that could bring some hurdles in terms of registration, especially in the case of the 279 development of a new drug product. It was possible to find, for example, papers that used albumin as an 280 excipient [63, 69, 79] , which is commonly used to induce asthma in animal models [92] , so is an dangerous 281 excipient for pulmonary delivery. Albumin was also employed (Table 1 ) and is not on the list of 282 excipients approved by the FDA for the inhalation route [91] . 283

Concerning in vitro and in vivo evaluations, there is also insufficient data, as might be expected. 284

In both cases, only about 50% of the studies make some evaluation in this regard. This means that half of 285 the reports develop formulations, but do not assess them properly to confirm the expected effects. In 286 addition, even fewer are the articles that performed both in vitro and in vivo tests (Table 3) , a sign that the 287 majority did not seek a correlation between them. With this gap, it appears that the correlation between 288 the physicochemical characterization of formulations and their biological impact is not a standard goal in 289 academic work. It should also be noted that in the case of in vitro tests, there is no standardization 290 between them, either in terms of the type of study, or in relation to the parameters used in the 291 measurement (Table 2) . 292

It is important to stand out that the dissolution test, which is extensively used for oral 293 administration drugs, does not have a standard pharmacopeial methodology or aerosols' regulatory 294 requirements. One of the main difficulties in standardizing an effective dissolution method for inhaled 295 formulations is that the drug dissolution process in the lung has many peculiarities, such as the extremely 296 low volume of pulmonary fluid (10 to 30 mL), the variable amount of particles reaching the lung, which 297

is not equivalent to the total amount of particles inhaled, the pulmonary fluids, which are composed of 298 several surfactants, among others [93, 94] . Therefore, an ideal method should perform, before the 299 dissolution itself, the collection of the relevant dosage respirable fraction (RF), in addition to using the 300 appropriate components to simulate the lung environment in vivo [94] . 301

However, among studies evaluated in this paper, less than 30% investigated RF, and for both 302 doxycycline and oseltamivir, none of the proposed formulations were evaluated regarding this parameter 303 (Table 3) . On the other hand, the fine particles fraction (FPF) was assessed in more than 65% of the 304 studies (Table 3) . This parameter deals with the percentage of particles smaller than a certain size, in 305 micrometers, according to the type of impactor used for the test. [94] . Beside de FPF has been measured 306 in 65% of the articles, the use of theses information for in vitro and in vivo study are not sufficient, since 307 RF refers to the ratio between FPF and the recovered dose [94] . So ideally, it is necessary to calculate 308 both parameters. According to the FDA, the isolated assessment of MMAD, GSD or FPF values cannot 309 be considered appropriate, so, the acceptance criteria should be based on the amount of drug retained in 310 each one of all the stages of the cascade impactor [87] . 311

It is important to highlight that advances in academic and scientific scenarios do not always 312 follow the regulatory scope and vice versa. There are many studies showing promising results but that do 313 not detail important aspects that would be necessary in the case of registering a drug product. On the other 314 hand, the legislation already available on this subject does not always present a more detailed framework 315 in the light of scientific advances in the area. These divergences are usually more common in developing 316 countries, whose regulatory scenario is still in consolidation [95] . 317

Thus, at least in the universe of drugs defined in the present study, scientific articles do not 318 always consider the current regulatory guidelines, that standardized tests in pharmacopoeias are not 319 followed and that there is a considerable range of articles with insufficient results to prove their 320 assumptions regarding the benefits of the formulations developed. It can be concluded, therefore, that 321 although there has been some progress in the development of formulations for the pulmonary route with 322 12 potential impact in the treatment of COVID-19, there is still a lot to be done, especially regarding projects 323 that reflect the regulatory scope and that aim industrial application of the results. 324 325 4.

The pulmonary administration of drugs is a route that presents quite satisfactory results for 327 respiratory diseases and, since that region is the gateway to the new coronavirus, the repositioning of 328 drugs for administration throughout this route is an interesting strategy. 329

However, the present study showed that pulmonary formulations containing promising drugs for 330 the treatment of COVID-19 are still scarce and almost all of them are not always based on current 331 regulatory guidelines. In addition, many of the articles found did not perform a complete evaluation of 332 their effectiveness, lacking results that prove the benefits of the formulations in question. 333

It is important to highlight that based on emergency of COVID-19 pandemic, which needs some 334 fast solution, this paper focused on molecules who were already being evaluated in clinical trials. 335

However, in the future it is necessary also evaluate molecules with potential for specific anti-coronavirus 336 molecular actions that are not necessarily in ongoing clinical trials. 337

Despite this uninspiring scenario, it is believed that the pandemic represents an opportunity for 338 investment in research into alternative routes of release, stimulating the research and the investment by Docking score Glide score [17] J o u r n a l P r e -p r o o f Decrease of total proteins and proinflammatory 0,5

The produced particle showed good powder flow. Even with a 20x lower dose via the lung than the commercial oral dose, the particles were more [77] J o u r n a l P r e -p r o o f solvent evaporation and lyophilization and 31% after 4 days enzymes at the bronchoalveolar lavage with a 61% decrease of the cellular infiltrate. Improvement at the histopathology and growth of the respiratory flow with 68% resistance to methacholine.

effective in treating air model animals. The presence of PEI increases the particle size, but also the porosity and, thereby, improves the flow and aerodynamic size. Due to their larger size, these particles are also not recognized by macrophages. Finally, the particles formed with PEI had a greater release of the drug. Even with a 20x lower dose via the lung than the commercial oral dose, the particles were more effective in treating air model animals. The study did not present results of effectiveness of the use of the formulation in the treatment. however, it shows that the formulation did not present toxicity to macrophages in the pulmonary airways of rats or in human lung cells. 

Clinical trials on drug repositioning for COVID-19 treatment

Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes

The socio-economic implications of the coronavirus pandemic (COVID-19): A review

Importance and globalization status of good manufacturing practice (GMP) requirements for pharmaceutical excipients

Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications

Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations

Literature review as a research methodology: An overview and guidelines

Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach

Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19

Peptide-like and smallmolecule inhibitors against Covid-19

Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2

In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors

Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19

Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

In silico studies on therapeutic agents for COVID-19: Drug repurposing approach

SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective

The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast

Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection

Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock

Docking study of chloroquine and hydroxychloroquine interaction with RNA binding domain of nucleocapsid phospho-protein -an in silico insight into the comparative efficacy of repurposing antiviral drugs

Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19

Vinardo: A Scoring Function Based on Autodock Vina Improves Scoring, Docking, and Virtual Screening

idock: A multithreaded virtual screening tool for flexible ligand docking

Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography

Structural and functional modelling of SARS-CoV-2 entry in animal models

Molecular docking between human TMPRSS2 and SARS-CoV-2 spike protein: conformation and intermolecular interactions

Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: Integrated computational approach

Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2

Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an in silico assisted drug-repurposing study

Crystal structure of Nsp15 endoribonuclease <scp>NendoU</scp> from <scp>SARS-CoV</scp> -2

Peptide and peptide-based inhibitors of SARS-CoV-2 entry

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: A retrospective study in two designated hospitals in Anhui

Dysregulation of Immune Response in Patients With Coronavirus

Doxycycline Modulates Smooth Muscle Cell Growth, Migration, and Matrix Remodeling after Arterial Injury

Safety and Efficacy Review of Doxycycline

Natural estrogens for oral contraception

Formulation and evalution of montelukast sodium -chitosan based spray dried microspheres for pulmonary drug delivery

Different approaches in the treatment of obstructive pulmonary diseases

Application of novel nanotechnologies in asthma

Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism

Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

New delivery strategies for the old pentavalent antimonial drugs

Repurposing drugs as inhaled therapies in asthma

A study of the mechanism of the antiasthmatic action of inhaled budesonide

Inhalation of repurposed drugs to treat pulmonary hypertension

Analysis of Review Times for Recent 505(b)(2) Applications

Controlled release antibiotics for dry powder lung delivery

Formulation Optimization and Characterization of Spray Dried Microparticles for Inhalation Delivery of Doxycycline Hyclate

Highly porous crosslinked poly(ester-anhydride) microspheres with high loading efficiency

Antibacterial loaded spray dried chitosan polyelectrolyte complexes as dry powder aerosol for the treatment of lung infections

Characterization of a new aerosol antibiotic/adjuvant combination for the treatment of P. aeruginosa lung infections

The influence of formulation components on the aerosolisation properties of spray-dried powders

Barrier or carrier? Pulmonary surfactant and drug delivery

Pulmonary surfactant and drug delivery: Focusing on the role of surfactant proteins

A Comparison of the Expression and Metabolizing Activities of Phase I and II Enzymes in Freshly Isolated Human Lung Parenchymal Cells and Cryopreserved Human Hepatocytes

Aerosolizable modified-release particles of montelukast improve retention and availability of the drug in the lungs

Formulation development and in-vitro evaluation of montelukast sodium pressurized metered dose inhaler

Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers

Aerosolized Montelukast Polymeric Particles-An Alternative to Oral Montelukast-Alleviate Symptoms of Asthma in a Rodent Model

Cospray Dried Antibiotics for Dry Powder Lung Delivery

Preparation, characterization and pulmonary pharmacokinetics of xyloglucan microspheres as dry powder inhalation

Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery

Lecithin-based modified soft agglomerate composite microparticles for inhalable montelukast: Development, tolerability and pharmacodynamic activity

Montelukast-loaded nanostructured lipid carriers: Part II Pulmonary drug delivery and in vitro-in vivo aerosol performance

Aerosolizable modified-release particles of montelukast improve retention and availability of the drug in the lungs

Inhalation of Estradiol for Sustained Systemic Delivery

Formulation and physical characterization of large porous particles for inhalation

Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 5. Oseltamivir Carboxylate

Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment

Development of sustained release Oseltamivir phosphate dry powder inhaler: In-vitro and in-vivo Toxicological Studies

Pulmonary drug delivery strategies: A concise, systematic review

Design and Synthesis of Spherical Multicomponent Aggregates Composed of Core-Shell, Yolk-Shell, and Hollow Nanospheres and Their Lithium-Ion Storage Performances

Effect of process parameters on energy performance of spray drying with exhaust air heat recovery for production of high value particles

Guideline on the pharmaceutical quality of inhalation and nasal products, London, Committee for Medicinal Products for Human Use (CHMP)

Guidance for Industry: Metered dose inhaler (MDI) and dry powder inhaler (DPI) products -quality considerations

Dispõe sobre os ensaios de desempenho in vitro de medicamentos nasais e inalatórios orais., Diário Oficial da União, n. 74, seção 1

PLGA Ethionamide Nanoparticles for Pulmonary Delivery: Development and in vivo evaluation of dry powder inhaler

Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis

US Department of Health and Human Services

The Classical Ovalbumin Challenge Model of Asthma in Mice

Dissolution: A Critical Performance Characteristic of Inhaled Products?

Development and Approval of Inhaled Respiratory Drugs: A US Regulatory Science Perspective

J o u r n a l P r e -p r o o f

The high values of average geometric diameter and the low mass density of the formulations favoured the efficient entry of particles into the lungs and the prolonged release of the drug into the systemic circulation. Thus, the porous particles performed better compared to the conventional aerosol. [78] J o u r n a l P r e -p r o o f 

The proposed formulation was able to reach the lung with a lower dose and less adverse effects compared to the oral solution.